{"id":"bortezomib-dexamethasone-rituximab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bortezomib specifically targets the 26S proteasome, a complex responsible for degrading ubiquitinated proteins. By inhibiting this complex, bortezomib induces endoplasmic reticulum stress and activates pro-apoptotic pathways, ultimately leading to cancer cell death. This mechanism is particularly effective in multiple myeloma and mantle cell lymphoma cells.","oneSentence":"Bortezomib inhibits the 26S proteasome, disrupting protein degradation and inducing apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:58:36.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT02844322","phase":"PHASE4","title":"The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":35},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT01788020","phase":"PHASE3","title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2013-11","conditions":"Waldenström's Macroglobulinemia","enrollment":202},{"nctId":"NCT03697356","phase":"PHASE2","title":"R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia","status":"RECRUITING","sponsor":"Kosin University Gospel Hospital","startDate":"2019-03-06","conditions":"Waldenström's Macroglobulinemia","enrollment":54},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT01805557","phase":"PHASE2, PHASE3","title":"Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2013-02-04","conditions":"Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":108},{"nctId":"NCT00477412","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-03","conditions":"Mantle Cell Lymphoma","enrollment":107},{"nctId":"NCT01381692","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-20","conditions":"Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma","enrollment":9},{"nctId":"NCT01046006","phase":"PHASE2","title":"Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"Meletios A. Dimopoulos","startDate":"2007-03","conditions":"Waldenstrom's Macroglobulinemia","enrollment":59},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00581776","phase":"PHASE2","title":"Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-05","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT00711828","phase":"PHASE2","title":"Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08","conditions":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":21},{"nctId":"NCT00413959","phase":"PHASE2","title":"VELCADE,Rituximab,Cyclophosphamide and Decadron","status":"TERMINATED","sponsor":"Oncology Specialists, S.C.","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, B-Cell","enrollment":12},{"nctId":"NCT00504751","phase":"PHASE2","title":"Phase II Study of \"VIPER\" Chemotherapy in Rel/Ref DLBCL","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":15},{"nctId":"NCT01449344","phase":"PHASE3","title":"Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL","status":"UNKNOWN","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2009-05-09","conditions":"Mantle Cell Lymphoma","enrollment":128},{"nctId":"NCT02971982","phase":"PHASE1, PHASE2","title":"PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2016-10","conditions":"Treatment","enrollment":40},{"nctId":"NCT00250926","phase":"PHASE2","title":"Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-10","conditions":"Waldenstrom's Macroglobulinemia","enrollment":23},{"nctId":"NCT00740415","phase":"PHASE2","title":"Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2007-06","conditions":"Lymphoma","enrollment":39},{"nctId":"NCT01457144","phase":"PHASE2","title":"Study of Mantle Cell Lymphoma Treatment by RiBVD","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2011-10","conditions":"Mantle Cell Lymphoma","enrollment":76},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00832234","phase":"PHASE2","title":"Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2006-09","conditions":"Waldenstroms Macroglobulinemia","enrollment":59},{"nctId":"NCT00433537","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-05","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma","enrollment":77},{"nctId":"NCT00510887","phase":"PHASE2","title":"Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-01","conditions":"Lymphoma, Follicular","enrollment":14},{"nctId":"NCT00261612","phase":"PHASE2","title":"Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2005-01","conditions":"Lymphoma, Mantle-Cell","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Velcade","MabThera"],"phase":"phase_2","status":"active","brandName":"Bortezomib, Dexamethasone, Rituximab","genericName":"Bortezomib, Dexamethasone, Rituximab","companyName":"European Myeloma Network B.V.","companyId":"european-myeloma-network-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bortezomib inhibits the 26S proteasome, disrupting protein degradation and inducing apoptosis in cancer cells. Used for Multiple myeloma, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}